Enhancement of Solubility and Dissolution of BCS Class II Drugs Using Solid Dispersion Technique

Abstract

The purpose of this study was to develop a solvent evaporation technique for improving the solubility of poorly soluble drugs, such as fluvoxamine tablets. Fluvoxamine is an antidepressant medication that is a selective serotonin reuptake inhibitor (SSRI).
The goal is to enhance the biological performance of Fluvoxamine by using a solid dispersion method since the BCS class II medication has poor oral bioavailability and low water solubility. Methodology: The medication Fluvoxamine was created utilizing the solvent evaporation process. Fluvoxamine solid dispersions were made using various carriers in PEG 6000 and mannitol ratios of 1:1, 1:2, and 1:3.
Findings: Findings from Fluvoxamine solid dispersions made using the solid dispersion technique Lastly, a comparison of all the formulations reveals that formulation (SF3), which contains fluvoxamine and PEG 6000 (1:3), performs better.
We came to the conclusion that the solvent evaporation solid dispersion process improves the solubility of poorly soluble drugs. We also produced six Fluvovamine formulations (FDF1–FDF6), and FDF4 exhibits the highest drug release at the end of time (98.9±0.8%).